Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus standard background therapy in moderate to severe systemic lupus erythematosus
2021-000962-14Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in systemic lupus erythematosus (SLE), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Reduction in serum anti-dsDNA antibody titers. Started Apr 2021; status: completed.
02
Drugs
daratumumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2021-000962-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000962-14.